NCT01298934 - LBH589 (Panobinostat) for the Treatment of Myelofibrosis | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

September 30, 2009

Primary Completion Date

July 31, 2015

Study Completion Date

July 31, 2015

Conditions

Primary MyelofibrosisPolycythemia Vera, Post-Polycythemic Myelofibrosis PhasePost-Essential Thrombocythemia Related Myelofibrosis

Interventions

DRUG

LBH589

Dose escalation study starting at 20mg by mouth three times a week, given weekly for 24 weeks in the phase I portion of the study.

Trial Locations (1)

Icahn School of Medicine at Mount Sinai, New York